Astex Announces That the Phase 3 ASCERTAIN – Acute Myeloid Leukemia (AML) Clinical Study of Oral Hypomethylating Agent Decitabine and Cedazuridine Fixed-Dose Combination (ASTX727 or DEC-C) Met the Trial’s Primary Endpoint
The phase 3 ASCERTAIN – AML clinical study of decitabine and cedazuridine, administered orally as…